FDA Releases Final Risk Evaluation and Mitigation Strategies (REMS) for…
After three years of work the Food and Drug Administration (FDA) released its final Risk Evaluation and Mitigation Strategies…
Monthly Publications
In Depth
Subscribe Now
In Depth
coverage of timely
Life Science
Compliance issues
Subscribe Now
Browsing Tag
Opioid
FDA Opioid REMS Advisory Panel Focus on CME for Improving Practice
As we noted last week, Murray Kopelow, M.D., M.S., Chief Executive and Secretary for the Accreditation Council for Continuing…
FDA Pain REMS Advisory Committee to Include Presentations on Continuing…
Today, Murray Kopelow, M.D., M.S., Chief Executive and Secretary for the Accreditation Council for Continuing Medical Education…
FDA Turns to CME for Risk Evaluation and Mitigation Strategy (REMS) Pain…
According to a FDA memo and recent article in the RPM Report, “continuing medical education (CME) has been under attack in…